Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith A Johnson

Showing results (321-330 of 392) with videos related to

Pageof 40
Sort By:
Annals of Neurology|September 8, 2015
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissueMarta Marquié, Marc D Normandin, Charles R Vanderburg, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 8, 2026
Identifying early changes in imaging, plasma, and digital cognitive biomarkers that correspond to Alzheimer's disease pathology in the presence of autopsy-confirmed co-pathologiesCharles D Chen, Cinthya Aguero, Alexandra Melloni, et al.
Neurobiology of Aging|May 29, 2012
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer diseaseAdam S Fleisher, Kewei Chen, Xiaofen Liu, et al.
JAMA Neurology|July 18, 2019
Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older AdultsJennifer S Rabin, Hannah Klein, Dylan R Kirn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 5, 2013
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal agingKeith A Johnson, Reisa A Sperling, Christopher M Gidicsin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 24, 2025
Elevated serum cortisol associated with early-detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: The Framingham Heart StudyArash Salardini, Jayandra J Himali, Muhammad S Abdullah, et al.
Medrxiv : the Preprint Server for Health Sciences|July 17, 2025
BrainAge moderates associations between Alzheimer's disease biomarkers and cognitive decline: a meta-analysis across A4/LEARN, HABS and ADNI cohortsJorge Garcia Condado, Hannah M Klinger, Colin Birkenbihl, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer's DiseaseMabel Seto, Hannah M Klinger, Michelle Clifton, et al.
The Lancet. Neurology|May 16, 2016
Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control studyPanagiotis Fotiadis, Sanneke van Rooden, Jeroen van der Grond, et al.
Pageof 40

Showing results (321-330 of 392) with videos related to

Sort By:
Pageof 40
Annals of Neurology|September 8, 2015
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissueMarta Marquié, Marc D Normandin, Charles R Vanderburg, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 8, 2026
Identifying early changes in imaging, plasma, and digital cognitive biomarkers that correspond to Alzheimer's disease pathology in the presence of autopsy-confirmed co-pathologiesCharles D Chen, Cinthya Aguero, Alexandra Melloni, et al.
Neurobiology of Aging|May 29, 2012
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer diseaseAdam S Fleisher, Kewei Chen, Xiaofen Liu, et al.
JAMA Neurology|July 18, 2019
Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older AdultsJennifer S Rabin, Hannah Klein, Dylan R Kirn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 5, 2013
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal agingKeith A Johnson, Reisa A Sperling, Christopher M Gidicsin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 24, 2025
Elevated serum cortisol associated with early-detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: The Framingham Heart StudyArash Salardini, Jayandra J Himali, Muhammad S Abdullah, et al.
Medrxiv : the Preprint Server for Health Sciences|July 17, 2025
BrainAge moderates associations between Alzheimer's disease biomarkers and cognitive decline: a meta-analysis across A4/LEARN, HABS and ADNI cohortsJorge Garcia Condado, Hannah M Klinger, Colin Birkenbihl, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer's DiseaseMabel Seto, Hannah M Klinger, Michelle Clifton, et al.
The Lancet. Neurology|May 16, 2016
Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control studyPanagiotis Fotiadis, Sanneke van Rooden, Jeroen van der Grond, et al.
Pageof 40